Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Corvus Pharmaceuticals, Inc. (CRVS)
Sector: Healthcare; Industry: Biotechnology

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2019-06-07 LEA LEIV Chief Financial Officer Buy 25,500 $3.49 $88,980 No
2018-12-21 LEA LEIV Chief Financial Officer Buy 24,700 $4.15 $102,409 No

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.

Insider Smart

Enphase Energy, Inc (ENPH) - ENPH was $10+ in 15Q1 then dropped to $2 and eventually went under $1. From 15Q4 to 17Q4 it built a 2-year-long base then BOOM! Stock went as high as $70 and likely will make a new high. Catch one or two moves like this you can retire early. One hint before the big move was that CEO and CFO were constantly accumulating, this kind of information is priceless.